A breast surgeon explains why patients should raise lymphedema with their care team at the start of treatment, and how early detection can make it reversible.
|Videos|December 20, 2019
Management of HER2 Expression in Breast Cancer
Author(s)Sponsored Content
Ian E. Krop, MD, PhD, provides insight on HER2 expression in breast cancer, treatment for blocking HER2, and the management of newly diagnosed HER2+ metastatic breast cancer with T-DM1.
Advertisement
Ian E. Krop, MD, PhD, provides insight on HER2 expression in breast cancer, treatment for blocking HER2, and the management of newly diagnosed HER2+ metastatic breast cancer with T-DM1.
Advertisement
Related to this article
A woman with stage 4 pancreatic cancer shares how a once-daily RAS inhibitor changed her energy, routine and time with family.
Brad Dugai and Russ Reed discuss symptom relief, skin-related side effects and challenges accessing Rasonque, a treatment for pancreatic cancer.
A nurse practitioner discusses how an app provides information on cancer treatments, potential side effects and preparing for medical appointments.
Final KEYNOTE-564 data show Keytruda after kidney cancer surgery lowered the risk of death by 30%. Dr. Toni Choueiri explains what it means for patients.
A physician emphasized how emotional support, reliable health information and caregiver involvement can encourage men to take a more proactive approach to prostate cancer screening and care.
Dr. Hope S. Rugo explains what KEYNOTE-B49 found about adding Keytruda to chemotherapy for PD-L1-positive, HR-positive, HER2-negative breast cancer.
A new trial will test whether a set course of Brukinsa plus sonrotoclax, which target two pathways that drive hairy cell leukemia, can offer an alternative to chemotherapy.
Advertisement
Advertisement
Trending on CURE
1
Why a Patient With Pancreatic Cancer Moved From Chemotherapy to Rasonque
2
Rasonque for Pancreatic Cancer: Patients Discuss Benefits, Risks and Access
3
FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer
4
5 Years of Pancreatic Cancer Advances: A Timeline of FDA Approvals and What They Mean for Patients
5